April 19, 2014 7:01 PM ET

Pharmaceuticals

Company Overview of Forma Therapeutics Holdings LLC

Company Overview

Forma Therapeutics Holdings LLC, through its subsidiary, develops cancer therapeutics. The company was incorporated in 2011 and is based in Watertown, Massachusetts.

500 Arsenal Street

Suite 100

Watertown, MA 02472

United States

Founded in 2011

Phone:

617-679-1970

Key Executives for Forma Therapeutics Holdings LLC

Executive Director
Compensation as of Fiscal Year 2013.

Forma Therapeutics Holdings LLC Key Developments

FORMA Therapeutics Holdings and Celgene Corp. Form Broad Strategic Collaboration

FORMA Therapeutics Holdings announced a strategic collaboration agreement with Celgene Corp. under which FORMA and Celgene will discover, develop and commercialize drug candidates to regulate protein homeostasis targets. Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins. The collaboration between FORMA and Celgene will be launched with an undisclosed up-front payment that will enable Celgene to evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, Celgene will have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the United States, in exchange for research and early development payments of up to $200 million to FORMA. Under the terms of the collaboration agreement, FORMA is incentivized to advance the full complement of drug candidates through phase 1, while Celgene will be responsible for all further global clinical development for each licensed candidate. FORMA is eligible to receive $315 million in potential payments based upon development, regulatory and sales objectives for the first ex-U.S. license. FORMA is also eligible to receive potential payments for successive licenses, which escalate for productivity increasing up to a maximum of $430 million per program. In addition, FORMA will receive royalties on ex-U.S. sales and additional payments if multiple drug candidates reach defined cumulative sales objectives, providing a significant incentive for FORMA to advance multiple drug candidates.

Forma Therapeutics Holdings LLC Presents at BioCentury Future Leaders in the Biotech Industry 2013, Apr-05-2013 03:30 PM

Forma Therapeutics Holdings LLC Presents at BioCentury Future Leaders in the Biotech Industry 2013, Apr-05-2013 03:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
PharmaNova, Inc. United States
NT Pharma, LLC United States
Bennu Pharmaceuticals Inc. United States
Veritas Research Inc. United States
Pharmachem Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Forma Therapeutics Holdings LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.